Tuesday, August 6, 2013

Clinical Collaboration Congress Session Spotlight: New Ways to Share Risk: Mergers and Acquisitions in the Industry - Near Term Solution to a Long-Term Problem?

Mergers and acquisition activity not only affects job stability but the future of a company’s drug development pipeline. It’s also crucial to pharmaceutical and biotech executives to understand the scope of activity in this space to ensure the stability of their outsourcing partners’ work because the consequences could cost millions of dollars. This year at the Clinical Collaboration Congress, we feature the session  New Ways to Share Risk: Mergers and Acquisitions in the Industry - Near Term Solution to a Long-Term Problem? session features leading finance experts with insights on how mergers and acquisitions in the pharmaceutical/CRO industry.

This September 25-27, 2013 in Boston, MA, the Clinical Collaboration Congress will address this topic and much more to improve the logistics behind clinical outsourcing.  For more information on this session and the rest of the program, download the agenda.  If you'd like to join us, as a reader of this blog when you register to join us and mention code XP1825BLOG, you'll save 15% off the standard rate.

Featured Session: New Ways to Share Risk: Mergers and Acquisitions in the Industry — Near Term Solution to a Long-Term Problem?

Featured Speakers:
  • - Michael Martorelli,Research Partner, Fairmount Partners
  • - John Kreger,Principal Healthcare Equity Research Analyst, William Blair & Company
  • - Dana Callow,Founder and General Manger, Boston Millennia Partners
About the session: Mergers and acquisitions in the pharmaceutical industry have substantially reduced the number of major companies over the past 15 years. The short-term business rationale for this extensive consolidation might have been reasonable, but at what cost to research and development productivity? Hear perspectives from Wall Street, VCs, pharma and finance experts come as they talk openly about strategic approaches to getting a greater return for their money, how they can reduce cost and develop greater ROI.




No comments: